<DOC>
	<DOCNO>NCT00059462</DOCNO>
	<brief_summary>The purpose study evaluate safety experimental drug Bay 50-4798 HIV positive patient receive HAART test drug 's effect CD4+ T-cell count .</brief_summary>
	<brief_title>Safety Efficacy BAY 50-4798 Patients With HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Documented HIV infection ( positive enzyme link immuno assay ( EIA ) confirm Western Blot ) . Age great equal 18 year . Plasma HIV viral load le 10,000 copies/ml ( bDNA assay less 14,000 copies/ml RTPCR ) least 2 occasion within 8 week prior study entry 0.5 log increase recent earlier viral load measurement . CD4 + Tcell count great equal 200/mm ( 3 ) least 2 occasion within 8 week study entry . On stable HAART regimen great equal 8 week . Karnofsky Score great equal 80 . Written informed consent . Prior treatment IL2 IL2 analogue . Pregnancy breastfeed . Use known immunomodulators , cytokine , growth factor systemic corticosteroid ( e.g . prednisone great equal 15 mg/day equivalent ) within 4 week prior study enrollment . History AIDS define illness Centers Disease Control ( CDC ) definition within 8 week prior study entry . Acute bacterial viral infection within 4 week prior enrollment . Received immunization within 4 week prior enrollment . History autoimmune disease include psoriasis , inflammatory bowel disease . Medical history transplantation ( solid organ bone marrow ) . Received investigational drug past 30 day Food Drug Administration ( FDA ) sanction treatment IND antiretroviral agent . Renal insufficiency serum creatinine level great 1.5 time upper limit normal . Bone marrow suppression define one following : granulocyte count le 1,000 cells/ÂµL ; hemoglobin less 9.0g ( female ) less 9.5g ( male ) ; platelet count less 75,000 cells/ÂµL . Evidence hepatic disease indicate one following : SGOT ( AST ) and/or SGPT ( ALT ) great 5 time upper limit normal . Bilirubin great 2 time upper limit normal ( except patient know Gilbert 's syndrome receiving indinavir may enrol serum bilirubin less equal 5 time upper limit normal ) . Active cardiac disease ( coronary artery disease , congestive heart failure cardiomyopathy ) require treatment follow medication : antiarrhythmic agent include digitalis , antianginal drug include topical systemic nitrate , calcium channel blocker , beta blocker , afterload reducer include ACE inhibitor . Patients require medication solely treatment hypertension remain eligible study . Presence significant cardiac insufficiency ( great equal New York Heart Association Grade 2 ) . Diagnosis active malignancy require treatment systemic cytotoxic chemotherapy . Active alcohol substance abuse , opinion investigator , seriously compromise subject 's ability adhere demand study . Any central nervous system ( CNS ) disease require active treatment anticonvulsant . Use antimetabolite hydroxyurea within 4 week prior study entry . Known coinfection Hepatitis B C virus unless serum transaminase less equal 2 time upper limit normal least two occasion within 8 week prior study entry . Known CD4 Nadir le 50 cells/mm ( 3 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Treatment experience</keyword>
</DOC>